ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,204Medicare Part D Prescriptions Filled, Including Refills

Rank: 640 out of 2888

$777K Total Retail Price of All Prescriptions

Rank: 387 out of 2888

327 Patients Receiving at Least One Drug in Part D
89%Patients 65 Years and Older
94% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Texas
Lower avg

Schedule Two
Controlled Substances

N/A

Schedule Three
Controlled Substances

17% of this provider’s 327 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

2% of this provider’s 8,565 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 2%.

Brand Name Drugs

33% of this provider’s prescriptions were for brand-name drugs, compared to an average of 27%.

Prescription Price

$84 was the average price of a prescription from this provider, compared to $67 among peers.

Prescriptions per Patient

28 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Texas
METOPROLOL SUCCINATE 594 552 1 11
ISOSORBIDE MONONITRATE ER 287 283 2 51
LEVOTHYROXINE SODIUM 272 255 3 1
ENALAPRIL MALEATE 246 218 4 49
NEXIUM 241 233 5 19
CRESTOR 207 198 6 20
FUROSEMIDE 199 187 7 6
SIMVASTATIN 183 175 8 2
POTASSIUM CHLORIDE 179 154 9 14
NIFEDIPINE ER 176 169 10 76
HYDRALAZINE HCL 164 158 11 59
METOPROLOL TARTRATE 162 151 12 10
ENOXAPARIN SODIUM 142 134 13 307
RANITIDINE HCL 135 130 14 56
TRAMADOL HCL 118 112 15 16
AZITHROMYCIN 113 99 16 38
TAMSULOSIN HCL 107 106 17 29
NOVOLOG MIX 70-30 107 100 17 209
DIOVAN HCT 104 86 19 61
LANTUS 98 96 20 45
NITROSTAT 95 94 21 240
MIRTAZAPINE 94 94 22 54
DONEPEZIL HCL 90 90 23 26
HYDROCODONE-ACETAMINOPHEN 89 75 S3 24 4
GLIMEPIRIDE 88 84 25 36
LISINOPRIL-HYDROCHLOROTHIAZIDE 87 82 26 28
ATORVASTATIN CALCIUM 87 82 26 9
JANUVIA 82 77 28 48
LIDODERM 80 77 29 105
AMLODIPINE BESYLATE 79 70 30 5
CLONIDINE HCL 77 73 31 39
GLIPIZIDE ER 74 64 32 107
NITROGLYCERIN PATCH 73 71 33 183
AVODART 73 71 33 151
ZOLPIDEM TARTRATE 72 59 35 17
CYMBALTA 72 68 35 44
DIOVAN 65 54 37 35
AMITRIPTYLINE HCL 65 52 R 37 74
HYDROCHLOROTHIAZIDE 63 55 39 15
CALCITRIOL 62 58 40 222
ALENDRONATE SODIUM 59 59 41 23
JANUMET 58 47 42 131
TRICOR 56 44 43 91
CARBIDOPA-LEVODOPA 55 55 44 113
CLOTRIMAZOLE-BETAMETHASONE 54 49 45 136
DIGOXIN 53 51 46 55
OMEPRAZOLE 52 50 47 7
ROPINIROLE HCL 52 52 47 115
PANTOPRAZOLE SODIUM 50 50 49 33
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on July 8, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.